Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

New England Journal of Medicine

Volumn 351, Issue 14, 2004, Pages

  Walsh, Thomas J ^a   Teppler, Hedy ^b   Donowitz, Gerald R ^c   Maertens, Johan A ^d   Baden, Lindsey R ^e   Dmoszynska, Anna ^f   Cornely, Oliver A ^g   Bourque, Michael R ^b   Lupinacci, Robert J ^b   Sable, Carole A ^b   DePauw, Ben E ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f I Independent Clinical Hospital Lublin   (Poland)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CREATININE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLOPEPTIDE; LIPOSOME; PEPTIDE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD UREA NITROGEN ELEVATION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EVALUATION; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SERUM ALANINE AMINOTRANSFERASE ELEVATION; SERUM ALKALINE PHOSPHATASE ELEVATION; SERUM ASPARTATE AMINOTRANSFERASE ELEVATION; SERUM CREATININE ELEVATION; SIDE EFFECT; SURVIVAL TIME; UREA NITROGEN BLOOD LEVEL; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; KIDNEY DISEASE; MIDDLE AGED; MORTALITY; NEOPLASM; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FEVER; HUMANS; KIDNEY DISEASES; LIPOSOMES; MALE; MIDDLE AGED; MYCOSES; NEOPLASMS; NEUTROPENIA; PEPTIDES; PEPTIDES, CYCLIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4644346490     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040446     Document Type: Article

References (27)

1. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993;17:Suppl 2:S487-S491.
2. Andriole VT. Infections with Aspergillus species. Clin Infect Dis 1993;17:Suppl 2: S481-S486.
3. Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow transplant: attributable mortality and risk factors. Cancer 1992;69:2653-62.
4. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
5. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
6. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63.
7. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001;135:412-22.
8. Winston DJ, Hathorn JW, Schuster MG, Shiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9.
9. Hughes WT, Armstrong D, Bodey GP, et al. 2000 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
10. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101-11.
11. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
12. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57.
13. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2326-32.
14. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997;41:2333-8.
15. Vazquez JA, Lynch M, Boikow D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-sensitive and azole-resistant Candida species. Antimicrob Agents Chemother 1997;41:1612-4.
16. Petraitiene R, Petraitis V, Groll A, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomarman antigenemia. Antimicrob Agents Chemother 2002;46:12-23.
17. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451-7.
18. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for treatment of candidal esophagitis. Clin Infect Dis 2001;33: 1529-35.
19. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-9.
20. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med 2002;347:2020-9.
21. Maertens J, Raad I, Petrikkos G, et al. Update of multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 27-30, 2002. Washington, D.C.: American Society for Microbiology, 2002. abstract.
22. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
23. Koch G, Carr G, Amara I, Stokes M, Urynink T. Categorical data analysis. In: Berry D, ed. Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker, 1990:414-21.
24. Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standard. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1997:M27-A.
25. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard, Wayne, Pa.: National Committee for Clinical Laboratory Standards, 2001:M38-A.
26. Walsh T, Adamson PC, Seibel NL, et al. Pharmacokinetics (PK) of caspofungin (CAS) in pediatric patients. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 27-30, 2002. Washington, D.C.: American Society for Microbiology, 2002. abstract.
27. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46:3001-12.